ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2337

Safety and Tolerability of NIM-1324, an Oral, Once-daily LANCL2 Agonist, in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study in Normal Healthy Volunteers

Andrew Leber, Raquel Hontecillas, Nuria Tubau Juni and Josep Bassaganya-Riera, NIMML Institute, Blacksburg, VA

Meeting: ACR Convergence 2023

Keywords: Biomarkers, clinical trial, immunology, Systemic lupus erythematosus (SLE), Treg cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2326–2351) SLE – Treatment Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic lupus erythematosus is a complex disease in which the immune system is dysfunctional at multiple levels including impaired regulatory responses, altered self-antigen processing and increased autoantibody production. LANCL2 is a novel therapeutic target that has been first targeted by a gut-restricted compound, omilancor, currently in clinical development for inflammatory bowel diseases. NIM-1324 functions through similar LANCL2-dependent immunometabolic mechanisms, increasing the suppressive capacity and stability of regulatory CD4+ T cells (Treg) while also supporting the metabolic demands of autophagy in phagocytes. The preclinical efficacy of NIM-1324 has been validated in NZB/W, MRL, and pristane-induced models of lupus and the preclinical safety has been demonstrated up to a NOAEL of 1,000 mg/kg/d.

Methods: Oral NIM-1324 was evaluated for safety and tolerability in normal healthy volunteers (n = 56) in a randomized, double-blind, placebo-controlled trial. Volunteers were randomized into five single ascending dose cohorts (250 – 1500 mg, p.o.) and three multiple ascending dose cohorts (250 – 1500 mg QD for seven days, p.o.). Safety and tolerability were assessed by adverse event (AE) reporting, vital signs, ECG, hematology, and clinical chemistry. Blood concentrations of NIM-1324 were measured. Whole blood gene expression and serum cytokines were analyzed as markers of target engagement.

Results: Single and seven-day dosing with NIM-1324 did not result in and SAEs or increases in total AE rates in individual dose cohorts and overall pooled active group relative to placebo. Oral NIM-1324 dosing did not result in any clinically significant findings by biochemistry, coagulation, ECG, hematology, or urinalysis. NIM-1324 was rapidly absorbed after oral dosing and did not accumulate over the seven-day dosing period. Plasma exposure of NIM-1324 was observed to scale in a dose-proportional manner within the range of 250 to 1000 mg/d. Using a whole blood transcriptomic signature developed during preclinical efficacy testing, NIM-1324 upregulated the mRNA expression of genes associated with mitochondrial metabolism and downregulated markers of phagocyte activation. The magnitude of effect in the 250 mg cohort was like those observed preclinically at maximally effective doses.

Conclusion: Oral treatment with NIM-1324 is well tolerated and safe in humans up to the tested limit dose of 1500 mg/d. Based on the observed safety, pharmacokinetics and target engagement profile, a first-in-patient clinical trial of NIM-1324 in systemic lupus erythematosus is currently planned.


Disclosures: A. Leber: None; R. Hontecillas: None; N. Tubau Juni: None; J. Bassaganya-Riera: Landos Biopharma, 3, 4, 8.

To cite this abstract in AMA style:

Leber A, Hontecillas R, Tubau Juni N, Bassaganya-Riera J. Safety and Tolerability of NIM-1324, an Oral, Once-daily LANCL2 Agonist, in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study in Normal Healthy Volunteers [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/safety-and-tolerability-of-nim-1324-an-oral-once-daily-lancl2-agonist-in-a-randomized-double-blind-placebo-controlled-phase-1-study-in-normal-healthy-volunteers/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/safety-and-tolerability-of-nim-1324-an-oral-once-daily-lancl2-agonist-in-a-randomized-double-blind-placebo-controlled-phase-1-study-in-normal-healthy-volunteers/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology